Mallinckrodt Plc (NYSE:MNK)

4.08
Delayed Data
As of Aug 16
 -0.01 / -0.24%
Today’s Change
3.85
Today|||52-Week Range
36.65
-74.18%
Year-to-Date
Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?
Aug 16 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Q2 2019 Earnings Call Transcript
Aug 06 / MotleyFool.com - Paid Partner Content
Here's Why Mallinckrodt Dropped 12% Today
Aug 15 / MotleyFool.com - Paid Partner Content
Why Mallinckrodt Stock Is Dropping Today
Aug 06 / MotleyFool.com - Paid Partner Content
Is Mallinckrodt (MNK) a Profitable Pick for Value Investors?
Aug 14 / Zacks.com - Paid Partner Content
Company News For Aug 6, 2019
Aug 06 / Zacks.com - Paid Partner Content
Mallinckrodt Enrolls First Patient in Liver Disease Study
Aug 13 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Q2 Earnings Beat Estimates
Aug 06 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
Aug 07 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close4.09
Today’s open4.10
Day’s range4.00 - 4.32
Volume5,282,342
Average volume (3 months)3,459,113
Market cap$473.4M
Data as of 6:30pm ET, 08/16/2019

Growth & Valuation

Earnings growth (last year)-336.68%
Earnings growth (this year)+5.58%
Earnings growth (next 5 years)-17.50%
Revenue growth (last year)-0.19%
P/E ratioNM
Price/Sales0.42
Price/Book0.16

Competitors

 Today’s
change
Today’s
% change
GRTSGritstone Oncology I...+0.75+8.30%
PRQRProQR Therapeutics N...+0.02+0.24%
BFRABiofrontera AG0.000.00%
MNOVMediciNova Inc+0.22+2.70%
Data as of 4:00pm ET, 08/16/2019

Financials

Next reporting dateNovember 11, 2019
EPS forecast (this quarter)$2.05
Annual revenue (last year)$3.2B
Annual profit (last year)-$3.6B
Net profit margin-112.64%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark C. Trudeau
EVP-Global Operations &
Digital Innovation Officer
Frank Scholz
Corporate headquarters
Staines-Upon-Thames, Surrey

Forecasts